Regulation of lipid peroxidation by pxdn in the pathogenesis and mechanism of Dilated Cardiomyopathy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035560

Enrollment

Unknown

Registered

2020-08-13

Start date

2020-08-12

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated Cardiomyopathy

Interventions

Dilated Cardiomyopathy group:Nil

Healthy adults group:Nil

Eligibility

Sex/Gender

All

Age

12 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Echocardiography showed that left ventricular end diastolic diameter (LVEDd) > 5.0cm (female) / > 5.5cm (male); 2. Echocardiography showed that left ventricular ejection fraction (LVEF) < 45%, left ventricular short axis shortening (lvfs) < 25%.

Exclusion criteria

Exclusion criteria: 1. Patients with hypertension, valvular heart disease, congenital heart disease or ischemic heart disease (excluded by coronary angiography), pulmonary heart disease and pericardial disease; 2. Patients with chronic lung, kidney, liver disease, rheumatic disease, immune disease and tumor; 3. Patients with infection, diabetes, hyperthyroidism and severe anemia; 4. Patients with history of trauma or surgery, pregnancy, age > 80 years and poor compliance in recent two weeks.

Design outcomes

Primary

Measure	Time frame
PXDN;MDA;4-HNE;	—

Countries

China

Contacts

Public ContactZhang Guogang

Xiangya Hospital of Central South University

zhangguogang@csu.edu.cn+86 13787087240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026